| Rx0000095 |
Salix Pharmaceuticals, Inc. |
03/31/2023 |
65649040001 |
PLENVU® (polyethylene glycol 3350, sodium ascorbate, sodium sulfate, ascorbic acid, sodium chloride and potassium chloride for oral solution), Kit |
Brand |
FDA |
01/01/2023 |
7.73 |
138.74 |
09/10/2033 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
03/31/2023 |
65649055102 |
RELISTOR® (methylnaltrexone bromide) 12mg/0.6mL, vial |
Brand |
FDA |
01/01/2023 |
8.71 |
153.85 |
12/30/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
03/31/2023 |
65649055103 |
RELISTOR® (methylnaltrexone bromide) PFS 12 mg/0.6mL, 7ct |
Brand |
FDA |
01/01/2023 |
60.96 |
1076.94 |
12/30/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
03/31/2023 |
65649055107 |
RELISTOR® (methylnaltrexone bromide) PFS 12 mg/0.6mL, vial |
Brand |
FDA |
01/01/2023 |
8.71 |
153.85 |
12/30/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
03/31/2023 |
65649055204 |
RELISTOR® (methylnaltrexone bromide) PFS 8 mg/0.4mL, 7ct |
Brand |
FDA |
01/01/2023 |
60.96 |
1076.94 |
12/30/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
03/31/2023 |
65649015090 |
RELISTOR® (methylnaltrexone bromide) Tablets 150mg, 90ct |
Brand |
FDA |
01/01/2023 |
145.87 |
2323.02 |
03/10/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
03/31/2023 |
65649000330 |
Trulance® (plecanatide) 3mg Tablets, 30 |
Brand |
FDA |
01/01/2023 |
30.49 |
538.67 |
06/05/2034 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
03/01/2019 |
Synergy Pharmaceuticals Inc. |
None |
1 |
Bausch Health acquired certain assets of Synergy Pharmaceuticals Inc. including Trulance in a transaction valued at approximately $200 million plus certain assumed liabilities. https://ir.bauschhealth.com/news-releases/2018/12-12-2018-113003808 |
411.78 |
388.47 |
2017 |
353.48 |
None |
None |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
03/31/2023 |
70194000330 |
Trulance® (plecanatide) 3mg Tablets, Blister Pack of 30 |
Brand |
Medispan |
01/01/2023 |
30.49 |
538.67 |
06/05/2034 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
03/01/2019 |
Synergy Pharmaceuticals Inc. |
None |
1 |
Bausch Health acquired certain assets of Synergy Pharmaceuticals Inc. including Trulance in a transaction valued at approximately $200 million plus certain assumed liabilities. https://ir.bauschhealth.com/news-releases/2018/12-12-2018-113003809 |
411.78 |
388.47 |
2017 |
353.48 |
None |
None |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
03/31/2023 |
65649065103 |
UCERIS® (budesonide) Rectal Aerosol, Foam, two 54 ml Canisters, 2 mg/actuation |
Brand |
FDA |
01/01/2023 |
52.49 |
813.29 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
03/31/2023 |
65649030303 |
XIFAXAN® (rifaximin) 550mg Tablets HUD 6 cards of 10, 60ct Card |
Brand |
FDA |
01/01/2023 |
184.47 |
3159.79 |
10/02/2029 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
03/31/2023 |
65649030302 |
XIFAXAN® (rifaximin) 550mg Tablets, 60ct |
Brand |
FDA |
01/01/2023 |
184.47 |
3159.79 |
10/02/2029 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
| Rx0000011 |
Sanofi |
03/31/2023 |
58468021004 |
AUBAGIO® (teriflunomide) 14 mg tablet - bottle of 30 |
Brand |
FDA |
01/03/2023 |
511.12 |
9029.72 |
02/04/2034 |
Single Source Drug |
None |
1 |
Sanofi acknowledges its role in preserving a sustainable health care system and in limiting our contribution to U.S. health care spending growth. Our approach to pricing our medicines responsibly balances:
• Our ambition to chase the miracles of science to improve people’s lives and ensure patients have access to the medicines they need now and in the future;
• Government policies; and
• Evolving trends in the marketplace.
Should Sanofi take list price actions during the fiscal year (Jan. 1 to Dec. 31) on any of our medicines, the guiding principle is to adhere to a level that is consistent with our approach on responsible pricing. Sanofi will annually disclose additional background if price actions trigger a prescription drug inflation rebate under the Inflation Reduction Act of 2022. The revised “Limited U.S. Price Increases” policy is effective as of January 1, 2023. Previous price increases were evaluated based on our policy originally established in 2016. More about our updated pricing policies can be found at: https://www.sanofi.us/en/corporate-responsibility/pricing-principles/limited-us-price-increases |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
In the U.S., generics of teriflunomide entered the market mid-March 2023, as per settlements with generic manufacturers in 2017. |
| Rx0000011 |
Sanofi |
09/30/2023 |
58468021004 |
AUBAGIO® (teriflunomide) 14 mg tablet - bottle of 30 |
Brand |
FDA |
07/01/2023 |
316.05 |
9345.77 |
08/04/2034 |
Innovator Multiple Source Drug |
None |
1 |
Sanofi acknowledges its role in preserving a sustainable health care system and in limiting our contribution to U.S. health care spending growth. Our approach to pricing our medicines responsibly balances:
• Our ambition to chase the miracles of science to improve people’s lives and ensure patients have access to the medicines they need now and in the future;
• Government policies; and
• Evolving trends in the marketplace.
Should Sanofi take list price actions during the fiscal year (Jan. 1 to Dec. 31) on any of our medicines, the guiding principle is to adhere to a level that is consistent with our approach on responsible pricing. Sanofi will annually disclose additional background if price actions trigger a prescription drug inflation rebate under the Inflation Reduction Act of 2022. The revised “Limited U.S. Price Increases” policy is effective as of January 1, 2023. Previous price increases were evaluated based on our policy originally established in 2016. More about our updated pricing policies can be found at: https://www.sanofi.us/en/corporate-responsibility/pricing-principles/limited-us-price-increases |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
In the U.S., generics of teriflunomide entered the market mid-March 2023, as per settlements with generic manufacturers in 2017. The patent expiration date of the last to expire patent was extended by six months of pediatric exclusivity from 4 February 2034 to 4 August 2034. |
| Rx0000011 |
Sanofi |
03/31/2023 |
58468021104 |
AUBAGIO® (teriflunomide) 7 mg tablet - bottle of 30 |
Brand |
FDA |
01/03/2023 |
511.12 |
9029.72 |
02/04/2034 |
Single Source Drug |
None |
1 |
Sanofi acknowledges its role in preserving a sustainable health care system and in limiting our contribution to U.S. health care spending growth. Our approach to pricing our medicines responsibly balances:
• Our ambition to chase the miracles of science to improve people’s lives and ensure patients have access to the medicines they need now and in the future;
• Government policies; and
• Evolving trends in the marketplace.
Should Sanofi take list price actions during the fiscal year (Jan. 1 to Dec. 31) on any of our medicines, the guiding principle is to adhere to a level that is consistent with our approach on responsible pricing. Sanofi will annually disclose additional background if price actions trigger a prescription drug inflation rebate under the Inflation Reduction Act of 2022. The revised “Limited U.S. Price Increases” policy is effective as of January 1, 2023. Previous price increases were evaluated based on our policy originally established in 2016. More about our updated pricing policies can be found at: https://www.sanofi.us/en/corporate-responsibility/pricing-principles/limited-us-price-increases |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
In the U.S., generics of teriflunomide entered the market mid-March 2023, as per settlements with generic manufacturers in 2017. |
| Rx0000011 |
Sanofi |
09/30/2023 |
58468021104 |
AUBAGIO® (teriflunomide) 7 mg tablet - bottle of 30 |
Brand |
FDA |
07/01/2023 |
316.05 |
9345.77 |
08/04/2034 |
Innovator Multiple Source Drug |
None |
1 |
Sanofi acknowledges its role in preserving a sustainable health care system and in limiting our contribution to U.S. health care spending growth. Our approach to pricing our medicines responsibly balances:
• Our ambition to chase the miracles of science to improve people’s lives and ensure patients have access to the medicines they need now and in the future;
• Government policies; and
• Evolving trends in the marketplace.
Should Sanofi take list price actions during the fiscal year (Jan. 1 to Dec. 31) on any of our medicines, the guiding principle is to adhere to a level that is consistent with our approach on responsible pricing. Sanofi will annually disclose additional background if price actions trigger a prescription drug inflation rebate under the Inflation Reduction Act of 2022. The revised “Limited U.S. Price Increases” policy is effective as of January 1, 2023. Previous price increases were evaluated based on our policy originally established in 2016. More about our updated pricing policies can be found at: https://www.sanofi.us/en/corporate-responsibility/pricing-principles/limited-us-price-increases |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
In the U.S., generics of teriflunomide entered the market mid-March 2023, as per settlements with generic manufacturers in 2017. The patent expiration date of the last to expire patent was extended by six months of pediatric exclusivity from 4 February 2034 to 4 August 2034. |
| Rx0000011 |
Sanofi |
09/30/2023 |
00024515010 |
ELITEK® (rasburicase) 1.5 mg vial/kit - 3 kits |
Brand |
FDA |
07/01/2023 |
62.58 |
3191.63 |
None |
Single Source Drug |
None |
1 |
Sanofi acknowledges its role in preserving a sustainable health care system and in limiting our contribution to U.S. health care spending growth. Our approach to pricing our medicines responsibly balances:
• Our ambition to chase the miracles of science to improve people’s lives and ensure patients have access to the medicines they need now and in the future;
• Government policies; and
• Evolving trends in the marketplace.
Should Sanofi take list price actions during the fiscal year (Jan. 1 to Dec. 31) on any of our medicines, the guiding principle is to adhere to a level that is consistent with our approach on responsible pricing. Sanofi will annually disclose additional background if price actions trigger a prescription drug inflation rebate under the Inflation Reduction Act of 2022. The revised “Limited U.S. Price Increases” policy is effective as of January 1, 2023. Previous price increases were evaluated based on our policy originally established in 2016. More about our updated pricing policies can be found at: https://www.sanofi.us/en/corporate-responsibility/pricing-principles/limited-us-price-increases |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000011 |
Sanofi |
09/30/2023 |
00024515175 |
ELITEK® (rasburicase) 7.5 mg vial/kit - 1 kit |
Brand |
FDA |
07/01/2023 |
104.30 |
5319.38 |
None |
Single Source Drug |
None |
1 |
Sanofi acknowledges its role in preserving a sustainable health care system and in limiting our contribution to U.S. health care spending growth. Our approach to pricing our medicines responsibly balances:
• Our ambition to chase the miracles of science to improve people’s lives and ensure patients have access to the medicines they need now and in the future;
• Government policies; and
• Evolving trends in the marketplace.
Should Sanofi take list price actions during the fiscal year (Jan. 1 to Dec. 31) on any of our medicines, the guiding principle is to adhere to a level that is consistent with our approach on responsible pricing. Sanofi will annually disclose additional background if price actions trigger a prescription drug inflation rebate under the Inflation Reduction Act of 2022. The revised “Limited U.S. Price Increases” policy is effective as of January 1, 2023. Previous price increases were evaluated based on our policy originally established in 2016. More about our updated pricing policies can be found at: https://www.sanofi.us/en/corporate-responsibility/pricing-principles/limited-us-price-increases |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000011 |
Sanofi |
09/30/2023 |
00024582411 |
JEVTANA® (cabazitaxel) 60 mg/1.5 mL vial kit - 1 kit |
Brand |
FDA |
07/01/2023 |
264.02 |
13465.19 |
04/27/2031 |
Single Source Drug |
None |
1 |
Sanofi acknowledges its role in preserving a sustainable health care system and in limiting our contribution to U.S. health care spending growth. Our approach to pricing our medicines responsibly balances:
• Our ambition to chase the miracles of science to improve people’s lives and ensure patients have access to the medicines they need now and in the future;
• Government policies; and
• Evolving trends in the marketplace.
Should Sanofi take list price actions during the fiscal year (Jan. 1 to Dec. 31) on any of our medicines, the guiding principle is to adhere to a level that is consistent with our approach on responsible pricing. Sanofi will annually disclose additional background if price actions trigger a prescription drug inflation rebate under the Inflation Reduction Act of 2022. The revised “Limited U.S. Price Increases” policy is effective as of January 1, 2023. Previous price increases were evaluated based on our policy originally established in 2016. More about our updated pricing policies can be found at: https://www.sanofi.us/en/corporate-responsibility/pricing-principles/limited-us-price-increases |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
As per patent litigation settlements with generic manufacturers, Sanofi expects generic competition in Q2/Q3 2029.
In addition to the method of treating patent referenced in the Patent Expiration Date field (US Patent No. 8,927,592), there are three other extant U.S. patents for this product (US Patent Nos. 7,241,907 expiring 10 June 2026, and 10,583,110 and 10,716,777 both having expiration dates of 27 October 2030. |
| Rx0000011 |
Sanofi |
03/31/2023 |
00024592001 |
KEVZARA® (sarilumab) 150 mg/1.14 mL pen - carton of 2 pens |
Brand |
FDA |
01/03/2023 |
231.93 |
4097.28 |
09/19/2031 |
Single Source Drug |
None |
1 |
Sanofi acknowledges its role in preserving a sustainable health care system and in limiting our contribution to U.S. health care spending growth. Our approach to pricing our medicines responsibly balances:
• Our ambition to chase the miracles of science to improve people’s lives and ensure patients have access to the medicines they need now and in the future;
• Government policies; and
• Evolving trends in the marketplace.
Should Sanofi take list price actions during the fiscal year (Jan. 1 to Dec. 31) on any of our medicines, the guiding principle is to adhere to a level that is consistent with our approach on responsible pricing. Sanofi will annually disclose additional background if price actions trigger a prescription drug inflation rebate under the Inflation Reduction Act of 2022. The revised “Limited U.S. Price Increases” policy is effective as of January 1, 2023. Previous price increases were evaluated based on our policy originally established in 2016. More about our updated pricing policies can be found at: https://www.sanofi.us/en/corporate-responsibility/pricing-principles/limited-us-price-increases |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000011 |
Sanofi |
03/31/2023 |
00024590801 |
KEVZARA® (sarilumab) 150 mg/1.14 mL syringe - carton of 2 syringes |
Brand |
FDA |
01/03/2023 |
231.93 |
4097.28 |
09/19/2031 |
Single Source Drug |
None |
1 |
Sanofi acknowledges its role in preserving a sustainable health care system and in limiting our contribution to U.S. health care spending growth. Our approach to pricing our medicines responsibly balances:
• Our ambition to chase the miracles of science to improve people’s lives and ensure patients have access to the medicines they need now and in the future;
• Government policies; and
• Evolving trends in the marketplace.
Should Sanofi take list price actions during the fiscal year (Jan. 1 to Dec. 31) on any of our medicines, the guiding principle is to adhere to a level that is consistent with our approach on responsible pricing. Sanofi will annually disclose additional background if price actions trigger a prescription drug inflation rebate under the Inflation Reduction Act of 2022. The revised “Limited U.S. Price Increases” policy is effective as of January 1, 2023. Previous price increases were evaluated based on our policy originally established in 2016. More about our updated pricing policies can be found at: https://www.sanofi.us/en/corporate-responsibility/pricing-principles/limited-us-price-increases |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000011 |
Sanofi |
03/31/2023 |
00024592201 |
KEVZARA® (sarilumab) 200 mg/1.14 mL pen - carton of 2 pens |
Brand |
FDA |
01/03/2023 |
231.93 |
4097.28 |
09/19/2031 |
Single Source Drug |
None |
1 |
Sanofi acknowledges its role in preserving a sustainable health care system and in limiting our contribution to U.S. health care spending growth. Our approach to pricing our medicines responsibly balances:
• Our ambition to chase the miracles of science to improve people’s lives and ensure patients have access to the medicines they need now and in the future;
• Government policies; and
• Evolving trends in the marketplace.
Should Sanofi take list price actions during the fiscal year (Jan. 1 to Dec. 31) on any of our medicines, the guiding principle is to adhere to a level that is consistent with our approach on responsible pricing. Sanofi will annually disclose additional background if price actions trigger a prescription drug inflation rebate under the Inflation Reduction Act of 2022. The revised “Limited U.S. Price Increases” policy is effective as of January 1, 2023. Previous price increases were evaluated based on our policy originally established in 2016. More about our updated pricing policies can be found at: https://www.sanofi.us/en/corporate-responsibility/pricing-principles/limited-us-price-increases |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000011 |
Sanofi |
03/31/2023 |
00024591001 |
KEVZARA® (sarilumab) 200 mg/1.14 mL syringe - carton of 2 syringes |
Brand |
FDA |
01/03/2023 |
231.93 |
4097.28 |
09/19/2031 |
Single Source Drug |
None |
1 |
Sanofi acknowledges its role in preserving a sustainable health care system and in limiting our contribution to U.S. health care spending growth. Our approach to pricing our medicines responsibly balances:
• Our ambition to chase the miracles of science to improve people’s lives and ensure patients have access to the medicines they need now and in the future;
• Government policies; and
• Evolving trends in the marketplace.
Should Sanofi take list price actions during the fiscal year (Jan. 1 to Dec. 31) on any of our medicines, the guiding principle is to adhere to a level that is consistent with our approach on responsible pricing. Sanofi will annually disclose additional background if price actions trigger a prescription drug inflation rebate under the Inflation Reduction Act of 2022. The revised “Limited U.S. Price Increases” policy is effective as of January 1, 2023. Previous price increases were evaluated based on our policy originally established in 2016. More about our updated pricing policies can be found at: https://www.sanofi.us/en/corporate-responsibility/pricing-principles/limited-us-price-increases |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000011 |
Sanofi |
03/31/2023 |
00024586201 |
Mozobil® (plerixafor) 24 mg/1.2 mL (20mg/mL) |
Brand |
FDA |
01/03/2023 |
652.12 |
9968.07 |
07/22/2023 |
Single Source Drug |
None |
1 |
Sanofi acknowledges its role in preserving a sustainable health care system and in limiting our contribution to U.S. health care spending growth. Our approach to pricing our medicines responsibly balances:
• Our ambition to chase the miracles of science to improve people’s lives and ensure patients have access to the medicines they need now and in the future;
• Government policies; and
• Evolving trends in the marketplace.
Should Sanofi take list price actions during the fiscal year (Jan. 1 to Dec. 31) on any of our medicines, the guiding principle is to adhere to a level that is consistent with our approach on responsible pricing. Sanofi will annually disclose additional background if price actions trigger a prescription drug inflation rebate under the Inflation Reduction Act of 2022. The revised “Limited U.S. Price Increases” policy is effective as of January 1, 2023. Previous price increases were evaluated based on our policy originally established in 2016. More about our updated pricing policies can be found at: https://www.sanofi.us/en/corporate-responsibility/pricing-principles/limited-us-price-increases |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
There are there are two extant U.S. patents for this product (US Patent Nos. 6,987,102 and 7,897,590), which both are directed to methods of using Mozobil® and both have expiration dates of July 22, 2023, which is the date reported in the Patent Expiration Date field. |
| Rx0000011 |
Sanofi |
03/31/2023 |
58468008001 |
Thymoglobulin® (anti-thymocyte globulin [rabbit]) - 25mg inj 1 Vial |
Brand |
FDA |
01/03/2023 |
48.61 |
1020.74 |
None |
Single Source Drug |
None |
1 |
Sanofi acknowledges its role in preserving a sustainable health care system and in limiting our contribution to U.S. health care spending growth. Our approach to pricing our medicines responsibly balances:
• Our ambition to chase the miracles of science to improve people’s lives and ensure patients have access to the medicines they need now and in the future;
• Government policies; and
• Evolving trends in the marketplace.
Should Sanofi take list price actions during the fiscal year (Jan. 1 to Dec. 31) on any of our medicines, the guiding principle is to adhere to a level that is consistent with our approach on responsible pricing. Sanofi will annually disclose additional background if price actions trigger a prescription drug inflation rebate under the Inflation Reduction Act of 2022. The revised “Limited U.S. Price Increases” policy is effective as of January 1, 2023. Previous price increases were evaluated based on our policy originally established in 2016. More about our updated pricing policies can be found at: https://www.sanofi.us/en/corporate-responsibility/pricing-principles/limited-us-price-increases |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000092 |
Santarus, Inc. |
03/31/2023 |
68012025820 |
CYCLOSET® (bromocriptine mesytate tablets) 0.8 mg tablets, 200 ct |
Brand |
FDA |
01/01/2023 |
75.56 |
1110.65 |
04/30/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
| Rx0000086 |
Seagen, Inc. |
06/30/2023 |
51144005001 |
ADCETRIS, 50mg, single-dose vial, packaged singly |
Brand |
FDA |
06/29/2023 |
408.00 |
10878.00 |
12/31/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000086 |
Seagen, Inc. |
12/31/2023 |
51144005001 |
ADCETRIS, 50mg, single-dose vial, packaged singly |
Brand |
FDA |
12/28/2023 |
424.00 |
11302.00 |
12/31/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
1) Seagen (formerly Seattle Genetics) does not believe information related to the unit sales volume in the U.S., cost increase factors, or change/improvement descriptions are in the public domain or otherwise publicly available. As a result, for these data elements, Seagen limits its response pursuant to Cal. Health & Safety Code § 127679(b). (2) As described in our publicly available financial disclosures, for ADCETRIS and our related ADC technology, we own ten patents in the United States and Europe that will expire between 2020 and 2031. However, the specific day and month of the patent expiration is not publicly available, though the Department of Healthcare Access and Information ("HCAI") portal does not permit Seagen to insert only a year for this data field. As a result, Seagen has entered "12/31/2031" for the "patent expiration date" field in order to submit a report to HCAI, though this does not reflect the actual date and month which Seagen's patents expire. In addition, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Seagen did not acquire this product from another manufacturer within the previous five years. As a result, we have left columns N-V blank because they are not applicable to this product. |
| Rx0000086 |
Seagen, Inc. |
03/31/2023 |
51144002001 |
PADCEV (enfortumab vedotin-ejfv) 20 mg lyophilized powder in a single-dose vial for reconstitution |
Brand |
FDA |
03/30/2023 |
99.00 |
2651.00 |
12/31/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
1) Seagen (formerly Seattle Genetics) does not believe information related to the unit sales volume in the U.S., cost increase factors, or change/improvement descriptions are in the public domain or otherwise publicly available. As a result, for these data elements, Seagen limits its response pursuant to Cal. Health & Safety Code § 127679(b). 2) As described in our publicly available financial disclosures, for PADCEV and our related ADC technology, we own, co-owned or have licensed the rights to fourteen patents in the United States and Europe that will expire between 2022 and 2031. However, the specific day and month of the patent expiration is not publicly available, though the Department of Health Care Access and Information ("HCAI") Portal does not permit Seagen to insert only a year for this data field. As a result, Seagen has entered "12/31/2031" for the "patent expiration date" field in order to submit a report to HCAI, though this does not reflect the actual date and month which Seagen's patents expire. In addition, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. |
| Rx0000086 |
Seagen, Inc. |
09/30/2023 |
51144002001 |
PADCEV (enfortumab vedotin-ejfv) 20 mg lyophilized powder in a single-dose vial for reconstitution |
Brand |
FDA |
09/28/2023 |
103.00 |
2754.00 |
12/31/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
1) Seagen (formerly Seattle Genetics) does not believe information related to the unit sales volume in the U.S., cost increase factors, or change/improvement descriptions are in the public domain or otherwise publicly available. As a result, for these data elements, Seagen limits its response pursuant to Cal. Health & Safety Code § 127679(b). 2) As described in our publicly available financial disclosures, for PADCEV and our related ADC technology, we own, co-owned or have licensed the rights to fourteen patents in the United States and Europe that will expire between 2022 and 2031. However, the specific day and month of the patent expiration is not publicly available, though the Department of Health Care Access and Information ("HCAI") Portal does not permit Seagen to insert only a year for this data field. As a result, Seagen has entered "12/31/2031" for the "patent expiration date" field in order to submit a report to HCAI, though this does not reflect the actual date and month which Seagen's patents expire. In addition, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. |
| Rx0000086 |
Seagen, Inc. |
03/31/2023 |
51144003001 |
PADCEV (enfortumab vedotin-ejfv) 30 mg lyophilized powder in a single-dose vial for reconstitution |
Brand |
FDA |
03/30/2023 |
148.50 |
3976.50 |
12/31/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
1) Seagen (formerly Seattle Genetics) does not believe information related to the unit sales volume in the U.S., cost increase factors, or change/improvement descriptions are in the public domain or otherwise publicly available. As a result, for these data elements, Seagen limits its response pursuant to Cal. Health & Safety Code § 127679(b). 2) As described in our publicly available financial disclosures, for PADCEV and our related ADC technology, we own, co-owned or have licensed the rights to fourteen patents in the United States and Europe that will expire between 2022 and 2031. However, the specific day and month of the patent expiration is not publicly available, though the Department of Health Care Access and Information ("HCAI") Portal does not permit Seagen to insert only a year for this data field. As a result, Seagen has entered "12/31/2031" for the "patent expiration date" field in order to submit a report to HCAI, though this does not reflect the actual date and month which Seagen's patents expire. In addition, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. |
| Rx0000086 |
Seagen, Inc. |
09/30/2023 |
51144003001 |
PADCEV (enfortumab vedotin-ejfv) 30 mg lyophilized powder in a single-dose vial for reconstitution |
Brand |
FDA |
09/28/2023 |
154.50 |
4131.00 |
12/31/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
1) Seagen (formerly Seattle Genetics) does not believe information related to the unit sales volume in the U.S., cost increase factors, or change/improvement descriptions are in the public domain or otherwise publicly available. As a result, for these data elements, Seagen limits its response pursuant to Cal. Health & Safety Code § 127679(b). 2) As described in our publicly available financial disclosures, for PADCEV and our related ADC technology, we own, co-owned or have licensed the rights to fourteen patents in the United States and Europe that will expire between 2022 and 2031. However, the specific day and month of the patent expiration is not publicly available, though the Department of Health Care Access and Information ("HCAI") Portal does not permit Seagen to insert only a year for this data field. As a result, Seagen has entered "12/31/2031" for the "patent expiration date" field in order to submit a report to HCAI, though this does not reflect the actual date and month which Seagen's patents expire. In addition, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. |
| Rx0000086 |
Seagen, Inc. |
12/31/2023 |
51144000212 |
TUKYSA, 150mg, 120 Count Oral Tablet per Bottle |
Brand |
FDA |
12/28/2023 |
2116.00 |
25630.00 |
03/25/2033 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000086 |
Seagen, Inc. |
12/31/2023 |
51144000260 |
TUKYSA, 150mg, 60 Count Oral Tablet per Bottle |
Brand |
FDA |
12/28/2023 |
1058.00 |
12815.00 |
03/25/2033 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000086 |
Seagen, Inc. |
12/31/2023 |
51144000160 |
TUKYSA, 50mg, 60 Count Oral Tablet per Bottle |
Brand |
FDA |
12/28/2023 |
526.00 |
6373.00 |
03/25/2033 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000121 |
Secura Bio, Inc. |
12/31/2023 |
73116021556 |
Copiktra Duvelisib Oral Capsule 15 MG, 56ct |
Brand |
FDA |
12/15/2023 |
2402.08 |
26422.84 |
05/17/2032 |
Single Source Drug |
None |
1 |
None |
1 |
Price increase is to help offset the costs of mandatory clinical trials and other regulatory costs. In addition, the company is still selling this product as a loss as well as not producing net income on a company basis at this time. Price increase is being taken to better position the product with its competitors. |
None |
09/30/2020 |
Verastem, Inc. |
35000000 |
None |
None |
12390.00 |
11800.00 |
2018 |
11800.00 |
None |
None |
| Rx0000121 |
Secura Bio, Inc. |
12/31/2023 |
73116022556 |
Copiktra Duvelisib Oral Capsule 25 MG, 56ct |
Brand |
FDA |
12/15/2023 |
2402.08 |
26422.84 |
05/17/2032 |
Single Source Drug |
None |
1 |
None |
1 |
Price increase is to help offset the costs of mandatory clinical trials and other regulatory costs. In addition, the company is still selling this product as a loss as well as not producing net income on a company basis at this time. Price increase is being taken to better position the product with its competitors. |
None |
09/30/2020 |
Verastem, Inc. |
35000000 |
None |
None |
12390.00 |
11800.00 |
2018 |
11800.00 |
None |
None |
| Rx0000028 |
Servier Pharmaceuticals LLC |
03/31/2023 |
72694095401 |
Oncaspar Injection Solution 750 UNIT/ML, 5 ML, Unit-Dose, Vial |
Brand |
FDA |
01/01/2023 |
2079.67 |
24322.13 |
06/01/2037 |
Single Source Drug |
None |
1 |
The pricing decisions are determined after careful consideration of many interdependent factors including, but not limited to, clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs. |
None |
Not applicable |
None |
04/16/2018 |
Shire Oncology |
None |
1 |
None |
14544.54 |
13467.17 |
1994 |
896.45 |
None |
Patent application pending |
| Rx0000028 |
Servier Pharmaceuticals LLC |
03/31/2023 |
72694061760 |
Tibsovo Oral Tablet 250 MG, 60 Each, Bottle |
Brand |
FDA |
01/01/2023 |
2105.80 |
32188.60 |
06/07/2039 |
Single Source Drug |
None |
1 |
The pricing decisions are determined after careful consideration of many interdependent factors including, but not limited to, clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs. |
None |
Not applicable |
None |
04/06/2021 |
Agios Pharmaceuticals |
None |
1 |
None |
28380.00 |
27420.75 |
2018 |
26115.00 |
None |
None |
| Rx0000542 |
Singular Dreamer, Ltd |
12/31/2023 |
83035121509 |
TM-Vite Rx #90 Tablets
ASCORBIC ACID 60 mg
RIBOFLAVIN 1.7 mg
NIACINAMIDE 20 mg
PYRIDOXINE 10 mg
FOLIC ACID 1 mg
CYANOCOBALAMIN 6 ug
BIOTIN 300 ug
PANTOTHENIC ACID 10 mg
THIAMINE MONONITRATE 1.5 mg |
Generic |
Medispan |
11/08/2023 |
259.20 |
562.50 |
None |
Innovator Multiple Source Drug |
1196 |
None |
Initial market analysis only took account of cost basis. During premarket launch this analysis was redone to take into account competitive products within the marketplace and price was adjust accordly. |
None |
See column 10 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000175 |
Sobi Inc |
03/31/2023 |
66658023407 |
KINERET (anakinra) 100 MG/0.67 ML SYRINGE. 7 syringes in 1 carton (.67 ML in 1 syringe). |
Brand |
FDA |
01/01/2023 |
95.42 |
1288.14 |
None |
Single Source Drug |
None |
1 |
Sobi, Inc., pricing decisions regarding the Wholesale Acquisition Cost (“WAC”) price of medication are determined after careful consideration of several interdependent factors, including but not limited to the clinical and economic value of the medicine. |
None |
This WAC increase is not necessitated by a change or improvement in the prescription drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000244 |
Sprout Pharmaceuticals, Inc. |
12/31/2023 |
58604021430 |
Addyi - FLIBANSERIN
100mg Oral Tablet, 30ct Bottle - [Qty:1] |
Brand |
FDA |
12/18/2023 |
306.50 |
829.00 |
05/09/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000221 |
Strides Pharma, Inc. |
03/31/2023 |
64380018202 |
Omeprazole NaHCO3 Powder 20mg/1.68gm, 30 |
Generic |
FDA |
03/07/2023 |
2320.90 |
2620.90 |
None |
Non-innovator Multiple Source Drug |
530 |
None |
The product was recently acquired from Par Pharmaceuticals. Strides began marketing the drug in November 2022 and set a low WAC relative to the rest of the market. In order to remain competitive Strides raise the WAC to the original PAR price of $2620.90. This is the same published WAC for other generic suppliers such as Ajanta and Oceanside. The brand Zegerid sold by Santarus WAC is currently $3306.82 |
None |
No change or improvement. WAC was increased to bring back in line with the rest of the market on this product |
None |
11/05/2022 |
Par Pharmaceuticals |
6 |
None |
None |
300.00 |
2620.90 |
2016 |
2620.90 |
None |
None |
| Rx0000221 |
Strides Pharma, Inc. |
03/31/2023 |
64380018302 |
Omeprazole NaHCO3 Powder 40mg/1.68gm, 30 |
Generic |
FDA |
03/07/2023 |
2320.90 |
2620.90 |
None |
Non-innovator Multiple Source Drug |
852 |
None |
The product was recently acquired from Par Pharmaceuticals. Strides began marketing the drug in November 2022 and set a low WAC relative to the rest of the market. In order to remain competitive Strides raise the WAC to the original PAR price of $2620.90. This is the same published WAC for other generic suppliers such as Ajanta and Oceanside. The brand Zegerid sold by Santarus WAC is currently $3306.82 |
None |
No change or improvement. WAC was increased to bring back in line with the rest of the market on this product |
None |
11/05/2022 |
Par Pharmaceuticals |
6 |
None |
None |
300.00 |
2620.90 |
2016 |
2620.90 |
None |
None |
| Rx0000005 |
Sumitomo Pharma America, Inc. |
12/31/2023 |
72974041501 |
Myfembree (40 mg relugolix, 1mg estradiol, and .5 mg norethindrone acetate) oral tablets 28 per bottle |
Brand |
FDA |
12/30/2023 |
81.50 |
1168.21 |
None |
Single Source Drug |
None |
1 |
Sumitomo Pharma America, Inc. has made the decision to increase the WAC price of the applicable product effective December 30th 2023. This price change is due to increases in the cost of business operations related to the product that are consistent with inflation over the past 12 months. |
None |
No change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000005 |
Sunovion Pharmaceuticals Inc. |
03/31/2023 |
63402020230 |
Aptiom 30 Tablets 200 MG 30 Pack |
Brand |
FDA |
01/01/2023 |
78.30 |
1198.80 |
05/06/2023 |
Single Source Drug |
None |
1 |
Sunovion has made the decision to increase the WAC price of the applicable product effective January 1st, 2023. This price change is due to increases in the cost of business operations related to the product that are consistent with inflation over the past 12 months. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000005 |
Sunovion Pharmaceuticals Inc. |
03/31/2023 |
63402020430 |
Aptiom 30 Tablets 400 MG 30 Pack |
Brand |
FDA |
01/01/2023 |
78.30 |
1198.80 |
05/06/2023 |
Single Source Drug |
None |
1 |
Sunovion has made the decision to increase the WAC price of the applicable product effective January 1st, 2023. This price change is due to increases in the cost of business operations related to the product that are consistent with inflation over the past 12 months. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000005 |
Sunovion Pharmaceuticals Inc. |
03/31/2023 |
63402020830 |
Aptiom 30 Tablets 800 MG 30 Pack |
Brand |
FDA |
01/01/2023 |
78.30 |
1198.80 |
05/06/2023 |
Single Source Drug |
None |
1 |
Sunovion has made the decision to increase the WAC price of the applicable product effective January 1st, 2023. This price change is due to increases in the cost of business operations related to the product that are consistent with inflation over the past 12 months. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000005 |
Sunovion Pharmaceuticals Inc. |
03/31/2023 |
63402020660 |
Aptiom 60 Tablets 600 MG 60 Pack |
Brand |
FDA |
01/01/2023 |
156.60 |
2397.60 |
05/06/2023 |
Single Source Drug |
None |
1 |
Sunovion has made the decision to increase the WAC price of the applicable product effective January 1st, 2023. This price change is due to increases in the cost of business operations related to the product that are consistent with inflation over the past 12 months. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
03/31/2023 |
27505000401 |
Apokyn Subcutaneous Solution Cartridge 30 MG/3ML Package Size 3 Package Quantiy 1 |
Brand |
FDA |
01/01/2023 |
157.21 |
1478.31 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
No change or improvement to the drug. |
None |
06/09/2020 |
US Worldmeds |
None |
1 |
Information regarding the purchase of the USWM CNS product line can be found in press releases, however, information regarding specific product pricing is not available. |
1100.00 |
1058.00 |
2004 |
995.00 |
None |
NDC 27505000401 is the inner level of a multi-level package. As such it is not listed separately on the FDA NDC Directory, it is instead included in the package description of NDC 2705000405. Supernus only markets the 27505000405 NDC. |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
03/31/2023 |
27505000405 |
Apokyn Subcutaneous Solution Cartridge 30 MG/3ML Package Size 3 Package Quantiy 5 |
Brand |
FDA |
01/01/2023 |
786.06 |
7391.57 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
No change or improvement to the drug. |
None |
06/10/2020 |
US Worldmeds |
None |
1 |
Information regarding the purchase of the USWM CNS product line can be found in press releases, however, information regarding specific product pricing is not available. |
5500.00 |
5290.00 |
2004 |
4975.00 |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
09/30/2023 |
70482007530 |
Osmolex ER Oral Tablet Extended Release 24 Hour 129 MG Package Size 30 Package Quantity 1 |
Brand |
FDA |
07/01/2023 |
53.81 |
597.32 |
02/15/2038 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
11/24/2021 |
Adamas Pharmaceuticals |
None |
1 |
Information regarding the purchase of Adamas Pharmaceuticals can be found in press releases, however, information regarding specific product pricing is not available. |
450.00 |
450.00 |
2018 |
450.00 |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
09/30/2023 |
70482007630 |
Osmolex ER Oral Tablet Extended Release 24 Hour 193 MG Package Size 30 Package Quantity 1 |
Brand |
FDA |
07/01/2023 |
53.81 |
597.32 |
02/15/2038 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
11/24/2021 |
Adamas Pharmaceuticals |
None |
1 |
Information regarding the purchase of Adamas Pharmaceuticals can be found in press releases, however, information regarding specific product pricing is not available. |
450.00 |
450.00 |
2018 |
450.00 |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
03/31/2023 |
17772012101 |
Oxtellar XR Oral Tablet Extended Release 24 Hour 150 MG Size 100 Package Quantity 1 |
Brand |
FDA |
01/01/2023 |
48.22 |
851.81 |
04/13/2027 |
Single Source Drug |
None |
1 |
None |
1 |
No change or improvement to the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
03/31/2023 |
17772012201 |
Oxtellar XR Oral Tablet Extended Release 24 Hour 300 MG Package Size 100 Package Quantity 1 |
Brand |
FDA |
01/01/2023 |
66.98 |
1183.38 |
04/13/2027 |
Single Source Drug |
None |
1 |
None |
1 |
No change or improvement to the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
03/31/2023 |
17772012301 |
Oxtellar XR Oral Tablet Extended Release 24 Hour 600 MG Package Size 100 Package Quantity 1 |
Brand |
FDA |
01/01/2023 |
122.64 |
2166.66 |
04/13/2027 |
Single Source Drug |
None |
1 |
None |
1 |
No change or improvement to the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
03/31/2023 |
17772010301 |
Trokendi XR Oral Capsule Extended Release 24 Hour 100 MG Package Size 100 Package Quantity 1 |
Brand |
FDA |
01/01/2023 |
179.63 |
3173.52 |
04/04/2028 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
No change or improvement to the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
03/31/2023 |
17772010330 |
Trokendi XR Oral Capsule Extended Release 24 Hour 100 MG Package Size 30 Package Quantity 1 |
Brand |
FDA |
01/01/2023 |
53.89 |
952.05 |
04/04/2028 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
No change or improvement to the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
03/31/2023 |
17772010401 |
Trokendi XR Oral Capsule Extended Release 24 Hour 200 MG Package Size 100 Package Quantity 1 |
Brand |
FDA |
01/01/2023 |
245.73 |
4341.15 |
04/04/2028 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
No change or improvement to the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
03/31/2023 |
17772010430 |
Trokendi XR Oral Capsule Extended Release 24 Hour 200 MG Package Size 30 Package Quantity 1 |
Brand |
FDA |
01/01/2023 |
73.72 |
1302.36 |
04/04/2028 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
No change or improvement to the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
03/31/2023 |
17772010101 |
Trokendi XR Oral Capsule Extended Release 24 Hour 25 MG Package Size 100 Package Quantity 1 |
Brand |
FDA |
01/01/2023 |
69.60 |
1229.64 |
04/04/2028 |
Single Source Drug |
None |
1 |
None |
1 |
No change or improvement to the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
03/31/2023 |
17772010130 |
Trokendi XR Oral Capsule Extended Release 24 Hour 25 MG Package Size 30 Package Quantity 1 |
Brand |
FDA |
01/01/2023 |
20.88 |
368.89 |
04/04/2028 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
No change or improvement to the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
03/31/2023 |
17772010201 |
Trokendi XR Oral Capsule Extended Release 24 Hour 50 MG Package Size 100 Package Quantity 1 |
Brand |
FDA |
01/01/2023 |
90.66 |
1601.73 |
04/04/2028 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
No change or improvement to the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
03/31/2023 |
17772010230 |
Trokendi XR Oral Capsule Extended Release 24 Hour 50 MG Package Size 30 Package Quantity 1 |
Brand |
FDA |
01/01/2023 |
27.20 |
480.51 |
04/04/2028 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
No change or improvement to the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
03/31/2023 |
27505011130 |
Xadago Oral Tablet 100 MG Size 30 Package Quantity 1 |
Brand |
FDA |
01/01/2023 |
84.41 |
1139.49 |
06/08/2027 |
Single Source Drug |
None |
1 |
None |
1 |
No change or improvement to the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
03/31/2023 |
27505011030 |
Xadago Oral Tablet 50 MG Package Size 30 Package Quantity 1 |
Brand |
FDA |
01/01/2023 |
84.41 |
1139.49 |
06/08/2027 |
Single Source Drug |
None |
1 |
None |
1 |
No change or improvement to the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |